OXYCODONE, URINE (to monitor for compliance with oxycodone/Oxycontin therapy)
|In House Availability||Stat or routine, 24 hours/7days|
|Principle||Competitive enzyme immunoassay using DRI technology.|
|Interpretation||Oxycodone is a semi-synthetic opioid analgesic that is frequently prescribed to patients suffering from moderate to severe pain associated with cancer or other chronic pain syndromes. It is available in immediate-release formulations, singly, or in combination with acetaminophen. Monitoring patient compliance with prescribed treatment regimens by urine drug testing may be effective in decreasing diversion and abuse of drugs such as OxyContin(R).
CUTOFF: 100 ng/mL
Drug Detection Period (approximate guideline) = 1-3 days.
Positive results are not confirmed unless detected as part of a Drug Screen Urine, Comprehensive. Confirmation can be performed as an "add on" test by special request if the specimen is available. Call the Clinical Chemistry/Toxicolgy Fellow (415-206-8590) if you have questions about confirmatory testing. At SFGH, 96% of positive screens for oxycodone are confirmed.
The assay is sensitive to oxycodone and its principal metabolite, oxymorphone. This assay is not sensitive to the other opiates, codeine, morphine, hydrocodone, hydromorphone, heroin, or 6-monoacetylmorphine. This assay does not cross-react against any of the other non-opiate narcotic analgesics, such as fentanyl, methadone, or meperidine.
|Stability||Minimum 1 week at 2-8°C|
|Turn around times||Screening results are reported within 1 to 8 hours.|
|References||1. Wu AHB, Broussard LA, Hoffman RS, Kwong TC, McKay C, Moyer TP, Otten EM, Welch SL, Wax P. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. Recommendations for the Use of Laboratory Tests to Support the Impaired and Overdosed Patients from the Emergency Department. Clin Chem 2003; 49:357-79.
|Last Updated||7/24/2015 5:41:43 PM|